Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


Hard to Treat Diseases, Inc. (OTCPK:HTDS) Targets Merger with Biotechnology Companymarketwire
Related Quotes
Symbol Price Change
HTDS.PK 0.0006 +0.0001
{"s" : "","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Hard to Treat Diseases, Inc. On Friday November 12, 2010, 4:01 pm EST

SHENZEN, CHINA--(Marketwire - 11/12/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) ( is targeting a merger with a Canadian biotechnology company that deals with blood transfusion products.

This biotechnology company, who wishes to remain anonymous at this stage of negotiations, is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin based blood substitutes. The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.

There is currently a shortfall of blood available for transfusions. Serious harmful side effects exist in the use of stored donor blood; specifically, the loss of Nitric Oxide (NO) from the recipients' blood creates a hazardous condition known as vasoconstriction. Due to the demand for blood and associated transfusions, there are an increasing number of clinical trials and process being developed to counteract the loss of NO from blood.

This up-and-coming biotech company plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.

HTDS has remained silent for the past several months as it worked on this deal is pleased with this merger opportunity and feels that it may be a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.

HTDS expects to be in a position to release the name of the merger candidate and the new appointee officers and all relevant data shortly. The company is of the opinion that this is a significant event that requires a public release.

More details to follow shortly.

About Mina Mar Group:

Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit to learn more.

Mina Mar Marketing Group, MMMG ( offers publicly traded companies a full array of services such as Investor Relations and maintenance investor awareness.

To be included in company's email database for press releases, "Friday Tips", industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at